(Q38654552)

English

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Eric Pujade-Lauraine

1

object named as

Eric Pujade-Lauraine

0 references

Tomasz Huzarski

8

object named as

Tomasz Huzarski

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Keiichi Fujiwara

14

object named as

Keiichi Fujiwara

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Isabelle Ray-Coquard

15

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Susana Banerjee

16

object named as

Susana Banerjee

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

author name string

Jonathan A Ledermann

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Frédéric Selle

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Val Gebski

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Richard T Penson

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Amit M Oza

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Jacob Korach

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Andrés Poveda

9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sandro Pignata

10

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Michael Friedlander

11

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Nicoletta Colombo

12

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Philipp Harter

13

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Joyce Liu

17

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Elizabeth S Lowe

18

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Ralph Bloomfield

19

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Patricia Pautier

20

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

SOLO2/ENGOT-Ov21 investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

25 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930469-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30469-2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38654552&oldid=2046324887"